Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 (glucagon-like peptide-1) receptor agonists — including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — are FDA-approved medications that produce measurable weight loss results. But without consistent progress tracking, patients miss critical data points that could optimize their treatment and accelerate outcomes.
Clinical data shows 15-22%% average body weight reduction over 72 weeks, but individual results vary significantly. By tracking your personal milestones — weight, measurements, energy levels, side effects — your physician can make data-driven adjustments that keep your progress on the fastest possible trajectory.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Track your GLP-1 journey through defined milestones — first 5 lbs lost, 5%% body weight reduction, 10%% threshold, and beyond. Each milestone triggers a physician review to ensure your protocol is optimized for continued progress.
Your tracked progress data — weight trends, side effect reports, metabolic markers — directly inform your physician's dose adjustment decisions. This data-driven approach replaces guesswork with evidence-based protocol refinements.
Your board-certified physician reviews your tracked data at every check-in. This creates a transparent, accountable treatment partnership where both you and your doctor can see exactly what is working and what needs adjustment.
Three landmark randomized controlled trials in the New England Journal of Medicine form the evidence base for FDA-approved GLP-1 weight management medications:
Telehealth prescribing of GLP-1 medications is fully legal in all 50 states when conducted by a properly licensed physician through a HIPAA-compliant platform. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not DEA-scheduled controlled substances — no in-person visit is required by federal or state telehealth law.
Adult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
Select your state to access GLP-1 treatment with integrated progress tracking and physician-monitored milestone reviews.
Patients in major US cities are tracking their GLP-1 weight loss milestones with our data-driven telehealth platform. Find your city below.
Our platform combines FDA-approved GLP-1 prescribing with integrated progress tracking — so every data point contributes to better outcomes.
Complete your initial health profile to establish baseline measurements — weight, BMI, health history, and treatment goals. This data becomes the foundation your physician uses to design your personalized GLP-1 protocol and set measurable targets.
A board-certified physician reviews your baseline data, conducts your telehealth consultation, and establishes specific, trackable weight loss milestones. Together you define what success looks like — in numbers, not vague promises.
Your FDA-approved GLP-1 medication ships to your door from a licensed US pharmacy. As your treatment progresses, you log results and your physician reviews your data at structured intervals — adjusting your protocol based on measurable outcomes, not assumptions.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
After your initial baseline assessment, you log key data points — weight, measurements, energy, appetite changes, and any side effects. Your physician reviews this tracked data at structured check-in intervals to make evidence-based adjustments to your GLP-1 protocol.
Most patients see measurable progress within the first 4-8 weeks. Key milestones include first 5 lbs lost, 5%% body weight reduction (typically months 2-3), 10%% reduction (months 4-6), and 15-22%% total reduction over 12-18 months. Your physician sets personalized targets based on your baseline data.
Data-driven treatment outperforms standard prescribing because your physician can identify trends, detect plateaus early, and make proactive dose adjustments. Patients who track their progress consistently achieve better outcomes because their treatment is continuously optimized based on real results.
Both semaglutide (Wegovy) and tirzepatide (Zepbound) produce significant, measurable weight loss. Tirzepatide tends to show faster initial results (up to 22%% average), while semaglutide (up to 15%% average) has a longer track record. Your physician recommends based on your profile and tracking goals.
Yes — that is the core of our platform. Everything happens remotely: your baseline assessment, physician consultations, progress logging, milestone reviews, and dose adjustments. Track your weight loss journey from anywhere in all 50 states without a single office visit.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
